Nasdaq puts Top KingWin (WAI) under one-year listing monitor
Rhea-AI Filing Summary
Top KingWin Ltd has regained compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2), according to a notification dated October 7, 2025. This means the company currently meets Nasdaq’s standard for the minimum trading price of its shares.
At the same time, Nasdaq has placed Top KingWin under a one-year Mandatory Panel Monitor under Listing Rule 5815(d)(4)(B). If the company again falls out of bid price compliance during this period, it will not receive any additional cure or compliance period and will instead receive a delist determination letter. Top KingWin would then be able to request a new hearing with a Nasdaq Hearings Panel, but its securities could ultimately be delisted from Nasdaq depending on the outcome.
Positive
- Regained Nasdaq bid-price compliance: Nasdaq confirmed Top KingWin now meets the minimum bid price requirement under Listing Rule 5550(a)(2), removing the immediate threat of non-compliance.
Negative
- Heightened delisting risk during one-year monitor: Under Listing Rule 5815(d)(4)(B), any new bid price deficiency within the one-year monitoring period will lead directly to a delist determination letter without an additional cure period.
Insights
Top KingWin regains Nasdaq compliance but faces stricter one-year monitoring.
Top KingWin Ltd has restored compliance with Nasdaq’s bid price rule 5550(a)(2), removing an immediate threat to its stock market listing. Meeting this rule means the company’s share price is again above Nasdaq’s required minimum, which is a prerequisite for staying on the exchange.
However, Nasdaq has placed the company under a one-year Mandatory Panel Monitor under Listing Rule 5815(d)(4)(B). If Top KingWin falls out of bid price compliance again within this monitoring window, it will not receive a standard cure or compliance period under Rule 5810(c)(2) and 5810(c)(3). Instead, it would automatically face a delist determination, with only the option to request a new hearing before a Panel.
This framework keeps the near-term listing risk elevated even after regaining compliance. The decisive factor will be whether the company can maintain its bid price through the full one-year monitoring period, since another deficiency would trigger a faster path toward potential delisting subject to any future hearing outcome.